Genprex’s Active Drug Ingredient Validated by Independent Medical Journal ‘Nature Medicine’

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors that the active ingredient in the biotech firm’s immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by independent researchers.